Saturday 26 July 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • 'No link' between MMR and autism

'No link' between MMR and autism

14 June 1999

The University College's Royal Free Hospital in London, UK, which lastyear declared that there may be a link between the combined measles-mumps-rubella vaccine and a syndrome characterized by autism and inflammatory bowel disease (Marketletter March 16, 1998), have found in a new study that the rate of autism is no higher among children inoculated with the vaccine than those who do not receive the shot.

A different group of researchers at the hospital, who identified 498 children with autism from government health registers, found no evidence to support a connection with the MMR vaccine. While the study showed the number of cases of autism has been increasing since 1979, there was no sign of a sharp rise following introduction of the vaccine in 1988.

The study did not rule out the possibility of a rare idiosyncratic response to MMR, but noted that if such an association does occur, it could not be identified in this large UK sample. In the study, published in The Lancet (June 12), the researchers expressed hope that the results will reassure patients and restore confidence in the vaccine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Biotechnology
WHO: measles outbreaks kill 31 in Romania, 4 in rest of Europe
13 July 2017




More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

FDA delays review of Bayer’s elinzanetant NDA
Pharmaceutical
FDA delays review of Bayer’s elinzanetant NDA
26 July 2025
Pharmaceutical
AstraZeneca’s Cristian Massacesi joins BMS executive team
26 July 2025
Biotechnology
Memo moving potravitug to Phase III despite primary endpoint miss
25 July 2025
Pharmaceutical
Impressive Humalog comparison sends Adocia shares skywards
25 July 2025
Biotechnology
Another negative development for Elevidys
25 July 2025
Pharmaceutical
New medicines recommended for approval by EMA’s CHMP
25 July 2025
Pharmaceutical
Potential to cut middlemen in US medicines pathway appeals to Roche
25 July 2025

Company Spotlight

A California-based biotech company aiming to deliver a new class of RNA therapeutics.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze